SCHEMBL5500186

SCHEMBL5500186

C[C@]12C[C@H](c3ccc(-c4ccc(F)cc4)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 4/20 0.79
▸ NR3C1 P04150 14/20 0.60
▸ PGR P06401 7/20 0.60
▸ CYP3A4 P08684 3/20 0.55
▸ CYP2D6 P10635 3/20 0.55
▸ CYP2C19 P33261 3/20 0.55
▸ CYP2C9 P11712 3/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ ALOX15 P16050 1/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ THPO P40225 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ NR1I2 O75469 1/20 0.55
▸ GMNN O75496 1/20 0.55
▸ ABCB11 O95342 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608161 0.93 AR (0.78) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL2120219 0.93 AR (0.78) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL2120217 0.93 AR (0.78) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL19664233 0.93 AR (0.78) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL2608148 0.91 AR (0.76) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL2122411 0.91 AR (0.76) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL11892241 0.91 AR (0.84) ARNR3C1PGRESR1ESR2
SCHEMBL2122412 0.91 AR (0.76) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL5500183 0.91 AR (0.83) ARNR3C1PGRCYP3A4CYP2D6
SCHEMBL993139 0.91 AR (0.83) ARNR3C1PGRCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148213-B2 Antigestagenically active steroids with a fluorinated 17α-alkyl chain SCHERING AG (DE) 2006-12-12 — — US claimed
US-20050080060-A1 Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-04-14 — — US claimed
US-6806263-B2 NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS SCHERING AG (DE) 2004-10-19 — — US claimed
US-20030134834-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain SCHERING AG (DE) 2003-07-17 — — US claimed
US-6503895-B2 Antigestagenically active steroids with a fluorinated 17α-alkyl chain SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-07 — — US claimed
US-20020045774-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-18 — — US claimed
EP-0970103-B1 ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN SCHERING AG (DE) 2002-04-17 — — EP claimed
US-6316432-B1 ANTIESTROGENS AND ANTIFERTILITY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-13 — — US claimed
EP-1365765-B1 THE USE OF ANTIGESTAGENS FOR INHIBITING ACCELERATED ENDOMETRIAL MATURATION DURING INFERTILITY TREATMENT BAYER SCHERING PHARMA AG (DE) 2007-07-25 — — EP disclosed
US-7148213-B2 Antigestagenically active steroids with a fluorinated 17α-alkyl chain SCHERING AG (DE) 2006-12-12 — — US disclosed
US-20050080060-A1 Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-04-14 — — US disclosed
US-6806263-B2 NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS SCHERING AG (DE) 2004-10-19 — — US disclosed
US-20040152684-A1 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-08-05 — — US disclosed
US-20030134834-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain SCHERING AG (DE) 2003-07-17 — — US disclosed
US-6503895-B2 Antigestagenically active steroids with a fluorinated 17α-alkyl chain SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-07 — — US disclosed
US-20020143000-A1 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-10-03 — — US disclosed
US-20020045774-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-18 — — US disclosed
EP-0970103-B1 ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN SCHERING AG (DE) 2002-04-17 — — EP disclosed
US-6316432-B1 ANTIESTROGENS AND ANTIFERTILITY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134834-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain HSD17B11, HSD3B1, CYP17A1 AR 149/4885NR3C1 52/4885PGR 71/4885
US-20020143000-A1 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment FSHR, GNRHR, NR5A1 AR 118/4885NR3C1 61/4885PGR 4/4885
US-20040152684-A1 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment FSHR, GNRHR, NR5A1 AR 118/4885NR3C1 61/4885PGR 4/4885
US-20020045774-A1 Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain HSD17B11, NR5A1, HSD3B1 AR 186/4885NR3C1 31/4885PGR 52/4885
US-20050080060-A1 Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain NR5A1, HSD17B11, CYP21A2 AR 126/4885NR3C1 17/4885PGR 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback